uniQure (NASDAQ:QURE) Upgraded to “Sell” by StockNews.com

uniQure (NASDAQ:QURE) was upgraded by research analysts at StockNews.com to a “sell” rating in a report released on Monday.

Several other brokerages have also recently commented on QURE. Mizuho dropped their price target on shares of uniQure from $7.00 to $6.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $24.00 price objective on shares of uniQure in a research note on Tuesday, July 16th. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price objective on shares of uniQure in a research note on Tuesday, July 9th. Finally, The Goldman Sachs Group upped their price objective on shares of uniQure from $6.00 to $10.00 and gave the company a “neutral” rating in a research note on Friday. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, uniQure has an average rating of “Hold” and an average price target of $18.60.

uniQure Price Performance

uniQure stock traded up $0.27 during midday trading on Monday, hitting $7.58. The company’s stock had a trading volume of 1,348,229 shares, compared to its average volume of 1,757,128. The company has a quick ratio of 9.27, a current ratio of 9.39 and a debt-to-equity ratio of 0.70. The stock’s 50-day moving average price is $6.02 and its 200-day moving average price is $5.53. uniQure has a 12 month low of $3.73 and a 12 month high of $11.35. The company has a market capitalization of $368.01 million, a PE ratio of -1.22 and a beta of 0.97.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($1.36) EPS for the quarter, missing the consensus estimate of ($1.31) by ($0.05). uniQure had a negative return on equity of 137.05% and a negative net margin of 1,027.52%. The business had revenue of $8.49 million during the quarter, compared to the consensus estimate of $2.58 million. Analysts anticipate that uniQure will post -4.4 earnings per share for the current fiscal year.

Hedge Funds Weigh In On uniQure

Hedge funds have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. increased its holdings in uniQure by 222.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,258 shares of the biotechnology company’s stock worth $42,000 after buying an additional 4,315 shares during the last quarter. Vanguard Personalized Indexing Management LLC acquired a new position in uniQure in the fourth quarter worth approximately $86,000. SG Americas Securities LLC acquired a new position in uniQure in the fourth quarter worth approximately $116,000. Virtu Financial LLC acquired a new position in uniQure in the fourth quarter worth approximately $195,000. Finally, Clear Harbor Asset Management LLC increased its holdings in uniQure by 35.2% in the second quarter. Clear Harbor Asset Management LLC now owns 48,000 shares of the biotechnology company’s stock worth $215,000 after buying an additional 12,500 shares during the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.